Cardiovascular Systems, Inc. (CSI) (Nasdaq: CSII) will host a live webcast of its fiscal 2012 second-quarter conference call on Tuesday, February 7, 2012, at 3:45 p.m. CT (4:45 p.m. ET). David L. Martin, president and chief executive officer, and Laurence L. Betterley, chief financial officer, will discuss the company’s results for its fiscal second-quarter ended December 31, 2011, and its financial outlook. The company will issue a post-market earnings release on February 7. To access the live webcast, go to the investor information section of the company’s website, www.csi360.com, on the day of the conference call and click on the webcast icon. A webcast replay will be available beginning at 7 p.m. CT the same day. To participate in the conference call, dial (888) 680-0860 and enter 50105170. Please dial in at least 10 minutes prior to the call. To pre-register for the call, log on to the following website: https://www.theconferencingservice.com/prereg/key.process?key=PMQCKQGEL. When joining the call, pre-registered participants can enter their PIN code, and other participants can press *0 to reach the operator, or wait on the line for operator assistance. If you do not have access to the Internet and want to listen to an audio replay of the conference call, dial (888) 286-8010 and enter access number 28270965. The audio replay will be available beginning at 8 p.m. CT on Tuesday, February 7, 2012, through 6 p.m. CT on Friday, February 10, 2012. About Cardiovascular Systems, Inc. Cardiovascular Systems, Inc., based in St. Paul, Minn., is a medical device company focused on developing and commercializing innovative solutions for treating vascular and coronary disease. The company’s Stealth 360°™, Diamondback 360 ® and Predator 360 ® PAD Systems treat calcified and fibrotic plaque in arterial vessels throughout the leg in a few minutes of treatment time, and address many of the limitations associated with existing surgical, catheter and pharmacological treatment alternatives. The U.S. FDA granted 510(k) clearance for the use of the Diamondback 360° in August 2007 and for the Stealth 360° in March 2011. To date, more than 59,000 PAD procedures have been performed using the Diamondback 360° and Stealth 360° in leading institutions across the United States. CSI has also commenced its ORBIT II Investigational Device Exemption clinical trial to evaluate the safety and effectiveness of its orbital technology in treating coronary arteries. The coronary system is limited by federal law to investigational use and is currently not commercially available in the United States.
For more information, visit the company’s website at www.csi360.com.